Evaluation of antidiabetic potential of methanolic extract of myrmecodia platytyrea tuber, in vivo and in vitro / Hasbullani Zakaria

Tubers of Myrmecodia platytytrea (Rubiaceae) has been used traditionally as an alternative therapy for the management of cancer and other inflammatory-related disorders. This plant is also believed to have the ability to lower blood glucose level. Nevertheless, no scientific proof is available on it...

Full description

Saved in:
Bibliographic Details
Main Author: Zakaria, Hasbullani
Format: Thesis
Language:English
Published: 2019
Online Access:https://ir.uitm.edu.my/id/eprint/83357/1/83357.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
id my-uitm-ir.83357
record_format uketd_dc
spelling my-uitm-ir.833572023-11-16T09:30:10Z Evaluation of antidiabetic potential of methanolic extract of myrmecodia platytyrea tuber, in vivo and in vitro / Hasbullani Zakaria 2019 Zakaria, Hasbullani Tubers of Myrmecodia platytytrea (Rubiaceae) has been used traditionally as an alternative therapy for the management of cancer and other inflammatory-related disorders. This plant is also believed to have the ability to lower blood glucose level. Nevertheless, no scientific proof is available on its anti-diabetic effect. Type 2 diabetes mellitus (T2DM) is one of the main non-communicable chronic diseases. Individuals present with T2DM have insulin resistance and usually develop insulin deficiency. The aim of this study was to investigate the potency of Myrmecodia platytytrea methanolic tuber extract (MPMTE) as an antihyperglycemic agent, in vitro and in vivo. Firstly, a simple and rapid high performance thin layer chromatography (HPTLC) technique was developed to measure the antioxidant (a direct HPTLCDPPH• assay) and hypoglycemic effects (HPTLC with α-amylase) of Myrmecodia platytyrea tuber extracts (methanol, ethanol, dichloromethane and ethyl acetate extracts). Then, in vitro hypoglycemic effects via α-amylase and α-glucosidase inhibitory assays were conducted on the MPMTE. Cytotoxicity study of MPMTE was done against BRIN-BD11, 3T3-L1 and L6 using MTT assay before glucose uptake of MPMTE in these cell lines was measured by using Glucose Uptake Assay Kit while expression of glucose metabolism-related genes of cells were determined by quantitative RT-PCR. Finally, in vivo antihyperglycaemic effect of MPMTE was investigated for therapeutic and prophylactic treatments. Hyperglycaemia was induced in fasted SD rats with STZ (45 mg/kg; i.p.). In the therapeutic study, rats were treated orally with MPMTE (100, 200 and 400 mg/kg) and metformin (positive control, 100 mg/kg) daily for 14 days while in the prophylactic study rats were given MPMTE (100, 200 and 400 mg/kg) for 28 days before STZ induction. Blood was taken each week to measure fasting blood glucose level and at the end of experiment, for other biochemistry analysis. Our results showed that stigmasterol was detected in all extracts using HPLTC. The highest free radical scavenging activity was observed in the ethanol extract, which is rich in polyphenols and flavonoids. Additionally, MPMTE had both α-amylase and α-glucosidase inhibitory activities. MPMTE showed no cytotoxicity against BRIN-BD11, 3T3-L1 and L6 cells with IC50 values of > 500 μg/mL following 48 h incubation. Furthermore, MPMTE (125, 250 and 500 μg/mL) were able to downregulate expression of G6Pase gene and upregulate GCK, SREBP- 1C, GLUT2 and GLUT4 genes against BRIN-BD11, 3T3-L1 and L6 cells, suggesting MPMTE regulated glucose metabolism. In the therapeutic study, STZ-induced diabetic rats treated with MPMTE (200 and 400 mg/kg) had significant decreased (p < 0.05) in fasting blood glucose, total cholesterol, triglycerides and low-density lipoprotein (LDL) with no significant changes in high-density lipoprotein (HDL) compared to STZ-induced untreated diabetic rats. Administration of MPMTE for 28 days prior to injection of STZ did not prevent the development of diabetes.In conclusion, MPMTE had strong antihyperglycaemic activity that inhibits glucose absorption in the intestine, modulate glucose metabolism, improving β-cell function, initiating insulin release and antioxidant, as well as anti-inflammatory effects due to the presence of high antioxidant compounds in MPMTE including polyphenolic acids, flavonoids and stigmasterol. Hence, MPMTE can be further developed into an adjuvant therapy for diabetic patients. 2019 Thesis https://ir.uitm.edu.my/id/eprint/83357/ https://ir.uitm.edu.my/id/eprint/83357/1/83357.pdf text en public phd doctoral Universiti Teknologi MARA (UiTM) Faculty of Pharmacy Hazizul Hasan, Mizaton
institution Universiti Teknologi MARA
collection UiTM Institutional Repository
language English
advisor Hazizul Hasan, Mizaton
description Tubers of Myrmecodia platytytrea (Rubiaceae) has been used traditionally as an alternative therapy for the management of cancer and other inflammatory-related disorders. This plant is also believed to have the ability to lower blood glucose level. Nevertheless, no scientific proof is available on its anti-diabetic effect. Type 2 diabetes mellitus (T2DM) is one of the main non-communicable chronic diseases. Individuals present with T2DM have insulin resistance and usually develop insulin deficiency. The aim of this study was to investigate the potency of Myrmecodia platytytrea methanolic tuber extract (MPMTE) as an antihyperglycemic agent, in vitro and in vivo. Firstly, a simple and rapid high performance thin layer chromatography (HPTLC) technique was developed to measure the antioxidant (a direct HPTLCDPPH• assay) and hypoglycemic effects (HPTLC with α-amylase) of Myrmecodia platytyrea tuber extracts (methanol, ethanol, dichloromethane and ethyl acetate extracts). Then, in vitro hypoglycemic effects via α-amylase and α-glucosidase inhibitory assays were conducted on the MPMTE. Cytotoxicity study of MPMTE was done against BRIN-BD11, 3T3-L1 and L6 using MTT assay before glucose uptake of MPMTE in these cell lines was measured by using Glucose Uptake Assay Kit while expression of glucose metabolism-related genes of cells were determined by quantitative RT-PCR. Finally, in vivo antihyperglycaemic effect of MPMTE was investigated for therapeutic and prophylactic treatments. Hyperglycaemia was induced in fasted SD rats with STZ (45 mg/kg; i.p.). In the therapeutic study, rats were treated orally with MPMTE (100, 200 and 400 mg/kg) and metformin (positive control, 100 mg/kg) daily for 14 days while in the prophylactic study rats were given MPMTE (100, 200 and 400 mg/kg) for 28 days before STZ induction. Blood was taken each week to measure fasting blood glucose level and at the end of experiment, for other biochemistry analysis. Our results showed that stigmasterol was detected in all extracts using HPLTC. The highest free radical scavenging activity was observed in the ethanol extract, which is rich in polyphenols and flavonoids. Additionally, MPMTE had both α-amylase and α-glucosidase inhibitory activities. MPMTE showed no cytotoxicity against BRIN-BD11, 3T3-L1 and L6 cells with IC50 values of > 500 μg/mL following 48 h incubation. Furthermore, MPMTE (125, 250 and 500 μg/mL) were able to downregulate expression of G6Pase gene and upregulate GCK, SREBP- 1C, GLUT2 and GLUT4 genes against BRIN-BD11, 3T3-L1 and L6 cells, suggesting MPMTE regulated glucose metabolism. In the therapeutic study, STZ-induced diabetic rats treated with MPMTE (200 and 400 mg/kg) had significant decreased (p < 0.05) in fasting blood glucose, total cholesterol, triglycerides and low-density lipoprotein (LDL) with no significant changes in high-density lipoprotein (HDL) compared to STZ-induced untreated diabetic rats. Administration of MPMTE for 28 days prior to injection of STZ did not prevent the development of diabetes.In conclusion, MPMTE had strong antihyperglycaemic activity that inhibits glucose absorption in the intestine, modulate glucose metabolism, improving β-cell function, initiating insulin release and antioxidant, as well as anti-inflammatory effects due to the presence of high antioxidant compounds in MPMTE including polyphenolic acids, flavonoids and stigmasterol. Hence, MPMTE can be further developed into an adjuvant therapy for diabetic patients.
format Thesis
qualification_name Doctor of Philosophy (PhD.)
qualification_level Doctorate
author Zakaria, Hasbullani
spellingShingle Zakaria, Hasbullani
Evaluation of antidiabetic potential of methanolic extract of myrmecodia platytyrea tuber, in vivo and in vitro / Hasbullani Zakaria
author_facet Zakaria, Hasbullani
author_sort Zakaria, Hasbullani
title Evaluation of antidiabetic potential of methanolic extract of myrmecodia platytyrea tuber, in vivo and in vitro / Hasbullani Zakaria
title_short Evaluation of antidiabetic potential of methanolic extract of myrmecodia platytyrea tuber, in vivo and in vitro / Hasbullani Zakaria
title_full Evaluation of antidiabetic potential of methanolic extract of myrmecodia platytyrea tuber, in vivo and in vitro / Hasbullani Zakaria
title_fullStr Evaluation of antidiabetic potential of methanolic extract of myrmecodia platytyrea tuber, in vivo and in vitro / Hasbullani Zakaria
title_full_unstemmed Evaluation of antidiabetic potential of methanolic extract of myrmecodia platytyrea tuber, in vivo and in vitro / Hasbullani Zakaria
title_sort evaluation of antidiabetic potential of methanolic extract of myrmecodia platytyrea tuber, in vivo and in vitro / hasbullani zakaria
granting_institution Universiti Teknologi MARA (UiTM)
granting_department Faculty of Pharmacy
publishDate 2019
url https://ir.uitm.edu.my/id/eprint/83357/1/83357.pdf
_version_ 1783736366889172992